The FDA has eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for six approved CAR T cell therapies targeting BCMA and CD19 antigens, used in multiple myeloma and certain leukemias and lymphomas. This regulatory shift stems from mature real-world evidence and established management protocols, making it easier for community centers to administer these therapies. Experts including the FDA's Vinay Prasad and industry analysts view this move as an acceleration in patient access to potentially curative cell therapies, reducing provider burden. Additionally, patient monitoring after treatment has been relaxed, with shortened restrictions on driving and proximity to healthcare facilities, further streamlining care delivery.